Major histocompatibility complex class II expression deficiency caused by a RFXANK founder mutation: A survey of 35 patients

Blood

Volumn 118, Issue 19, 2011, Pages 5108-5118

  Ouederni, Monia ^a   Vincent, Quentin B ^b,c   Frange, Pierre ^a   Touzot, Fabien ^a   Scerra, Sami ^d   Bejaoui, Mohamed ^e   Bousfiha, Aziz ^f   Levy, Yves ^d   Lisowska Grospierre, Barbara ^g   Canioni, Danielle ^a,b   Bruneau, Julie ^a,b   Debré, Marianne ^a   Blanche, Stéphane ^a,b   Abel, Laurent ^b,c   Casanova, Jean Laurent ^a,b,c,h   Fischer, Alain ^a,b,f   Picard, Capucine ^a,b,c  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c IMAGINE INSTITUTE   (France)

^d HENRI MONDOR HOSPITAL   (France)

^e CENTRE NATIONAL DE GREFFE DE MOELLE OSSEUSE   (Tunisia)

^f IBN ROCHD UNIVERSITY HOSPITAL   (Morocco)

^g INSERM   (France)

^h ROCKEFELLER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; IMMUNOGLOBULIN;

ADOLESCENT; ANTIBIOTIC PROPHYLAXIS; ARTICLE; BARE LYMPHOCYTE SYNDROME; CHILD; CLINICAL ARTICLE; FEMALE; GENE; GENE DELETION; GENE EXPRESSION; GENE MUTATION; HEALTH SURVEY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; IMMUNE FUNCTION TEST; INFANT; INFECTION; MALE; NORTH AFRICA; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; RFXANK GENE; SCHOOL CHILD;

EID: 81055126777     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-05-352716     Document Type: Article

References (50)

1. Villard J, Masternak K, Lisowska-Grospierre B, Fischer A, Reith W. MHC class II deficiency: a disease of gene regulation. Medicine (Baltimore). 2001;80(6):405-418. (Pubitemid 33070847)
2. Klein C, Lisowska-Grospierre B, LeDeist F, Fischer A, Griscelli C. Major histocompatibility complex class II deficiency: clinical manifestations, immunologic features, and outcome. J Pediatr. 1993;123(6):921-928. (Pubitemid 23353255)
3. Nonoyama S, Etzioni A, Toru H, et al. Diminished expression of CD40 ligand may contribute to the defective humoral immunity in patients with MHC class II deficiency. Eur J Immunol. 1998;28(2):589-598.
4. Saleem MA, Arkwright PD, Davies EG, Cant AJ, Veys PA. Clinical course of patients with major histocompatibility complex class II deficiency. Arch Dis Child. 2000;83(4):356-359.
5. Bejaoui M, Barbouche MR, Mellouli F, Largueche B, Dellagi K. [Primary immunologic deficiency by deficiency of HLA class II antigens: nine new Tunisian cases]. Arch Pediatr. 1998;5(10):1089-1093.
6. Casper JT, Ash RA, Kirchner P, Hunter JB, Havens PL, Chusid MJ. Successful treatment with an unrelated-donor bone marrow transplant in an HLA-deficient patient with severe combined immune deficiency ("bare lymphocyte syndrome"). J Pediatr. 1990;116(2):262-265. (Pubitemid 20056783)
7. Klein C, Cavazzana-Calvo M, Le Deist F, et al. Bone marrow transplantation in major histocompatibility complex class II deficiency: a single-center study of 19 patients. Blood. 1995;85(2):580-587.
8. Bonduel M, Pozo A, Zelazko M, et al. Successful related umbilical cord blood transplantation for graft failure following T cell-depleted nonidentical bone marrow transplantation in a child with major histocompatibility complex class II deficiency. Bone Marrow Transplant. 1999;24(4):437-440. (Pubitemid 29403454)
9. Godthelp BC, van Eggermond MC, Peijnenburg A, et al. Incomplete T-cell immune reconstitution in two major histocompatibility complex class II-deficiency/bare lymphocyte syndrome patients after HLA-identical sibling bone marrow transplantation. Blood. 1999;94(1):348-358. (Pubitemid 29300168)
10. Renella R, Picard C, Neven B, et al. Human leucocyte antigen-identical haematopoietic stem cell transplantation in major histocompatiblity complex class II immunodeficiency: reduced survival correlates with an increased incidence of acute graft-versus-host disease and pre-existing viral infections. Br J Haematol. 2006;134(5):510-516. (Pubitemid 44141717)
11. Siepermann M, Gudowius S, Beltz K, et al. MHC class II deficiency cured by unrelated mismatched umbilical cord blood transplantation: case report and review of 68 cases in the literature. Pediatr Transplant. 2011;15(4):E80-E86.
12. Al-Mousa H, Al-Shammari Z, Al-Ghonaium A, et al. Allogeneic stem cell transplantation using myeloablative and reduced-intensity conditioning in patients with major histocompatibility complex class II deficiency. Biol Blood Marrow Transplant. 2010;16(6):818-823.
13. Steimle V, Otten LA, Zufferey M, Mach B. Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency (or bare lymphocyte syndrome). Cell. 1993;75(1):135-146. (Pubitemid 23306027)
14. Masternak K, Barras E, Zufferey M, et al. A gene encoding a novel RFX-associated transactivator is mutated in the majority of MHC class II deficiency patients. Nat Genet. 1998;20(3):273-277. (Pubitemid 28507672)
15. Steimle V, Durand B, Barras E, et al. A novel DNA-binding regulatory factor is mutated in primary MHC class II deficiency (bare lymphocyte syndrome). Genes Dev. 1995;9(9):1021-1032.
16. Durand B, Sperisen P, Emery P, et al. RFXAP, a novel subunit of the RFX DNA binding complex is mutated in MHC class II deficiency. EMBO J. 1997;16(5):1045-1055. (Pubitemid 27113183)
17. Masternak K, Muhlethaler-Mottet A, Villard J, Zufferey M, Steimle V, Reith W. CIITA is a transcriptional coactivator that is recruited to MHC class II promoters by multiple synergistic interactions with an enhanceosome complex. Genes Dev. 2000;14(9):1156-1166. (Pubitemid 30324428)
18. Godthelp BC, Van Eggermond MC, Van Tol MJ, Vossen JM, van den Elsen PJ. T cell immune reconstitution after allogeneic bone marrow transplantation in bare lymphocyte syndrome. Hum Immunol. 2000;61(9):898-907.
19. Peijnenburg A, Van Eggermond MC, Van den Berg R, Sanal O, Vossen JM, Van den Elsen PJ. Molecular analysis of an MHC class II deficiency patient reveals a novel mutation in the RFX5 gene. Immunogenetics. 1999;49(4):338-345. (Pubitemid 29119044)
20. Villard J, Lisowska-Grospierre B, van den Elsen P, Fischer A, Reith W, Mach B. Mutation of RFXAP, a regulator of MHC class II genes, in primary MHC class II deficiency. N Engl J Med. 1997;337(11):748-753. (Pubitemid 27417974)
21. Hauber I, Gulle H, Wolf HM, Maris M, Eggenbauer H, Eibl MM. Molecular characterization of major histocompatibility complex class II gene expression and demonstration of antigenspecific T cell response indicate a new phenotype in class II-deficient patients. J Exp Med. 1995;181(4):1411-1423.
22. Peijnenburg A, Godthelp B, van Boxel-Dezaire A, van den Elsen PJ. Definition of a novel complementation group in MHC class II deficiency. Immunogenetics. 1995;41(5):287-294.
23. Wolf HM, Thon V, Gulle H, Lechleitner S, Eibl MM, Petzelbauer P. Residual expression of functional MHC class II molecules in twin brothers with MHC class II deficiency is cell type specific. Br J Haematol. 2001;115(2):460-471. (Pubitemid 34203517)
24. Bontron S, Steimle V, Ucla C, Eibl MM, Mach B. Two novel mutations in the MHC class II transactivator CIITA in a second patient from MHC class II deficiency complementation group A. Hum Genet. 1997;99(4):541-546. (Pubitemid 27152107)
25. Fondaneche MC, Villard J, Wiszniewski W, et al. Genetic and molecular definition of complementation group D in MHC class II deficiency. Hum Mol Genet. 1998;7(5):879-885. (Pubitemid 28221252)
26. Quan V, Towey M, Sacks S, Kelly AP. Absence of MHC class II gene expression in a patient with a single amino acid substitution in the class II transactivator protein CIITA. Immunogenetics. 1999;49(11-12):957-963. (Pubitemid 29425236)
27. Nagarajan UM, Peijnenburg A, Gobin SJ, Boss JM, van den elsen PJ. Novel mutations within the RFX-B gene and partial rescue of MHC and related genes through exogenous class II transactivator in RFX-B-deficient cells. J Immunol. 2000;164(7):3666-3674. (Pubitemid 30169821)
28. Wiszniewski W, Fondaneche MC, Lambert N, et al. Founder effect for a 26-bp deletion in the RFXANK gene in North African major histocompatibility complex class II-deficient patients belonging to complementation group B. Immunogenetics. 2000;51(4-5):261-267. (Pubitemid 30198880)
29. Lennon-Duménil AM, Barbouche MR, Vedrenne J, et al. Uncoordinated HLA-D gene expression in a RFXANK-defective patient with MHC class II deficiency. J Immunol. 2001;166(9):5681-5687. (Pubitemid 32374192)
30. Wiszniewski W, Fondaneche MC, Le Deist F, et al. Mutation in the class II trans-activator leading to a mild immunodeficiency. J Immunol. 2001;167(3):1787-1794. (Pubitemid 32703183)
31. Wiszniewski W, Fondaneche MC, Louise-Plence P, et al. Novel mutations in the RFXANK gene: RFX complex containing in-vitro-generated RFXANK mutant binds the promoter without transactivating MHC II. Immunogenetics. 2003;54(11):747-755. (Pubitemid 36384468)
32. Prod'homme T, Dekel B, Barbieri G, et al. Splicing defect in RFXANK results in a moderate combined immunodeficiency and long-duration clinical course. Immunogenetics. 2003;55(8):530-539. (Pubitemid 37491671)
33. Nekrep N, Jabrane-Ferrat N, Wolf HM, Eibl MM, Geyer M, Peterlin BM. Mutation in a winged-helix DNA-binding motif causes atypical bare lymphocyte syndrome. Nat Immunol. 2002;3(11):1075-1081. (Pubitemid 35363661)
34. Rezaei N, Aghamohammadi A, Moin M, et al. Frequency and clinical manifestations of patients with primary immunodeficiency disorders in Iran: update from the Iranian Primary Immunodeficiency Registry. J Clin Immunol. 2006;26(6):519-532. (Pubitemid 44764262)
35. Al-Herz W, Zainal ME, Salama M, et al. Primary immunodeficiency disorders: survey of pediatricians in Kuwait. J Clin Immunol. 2008;28(4):379-383.
36. Reda SM, Afifi HM, Amine MM. Primary immunodeficiency diseases in Egyptian children: a singlecenter study. J Clin Immunol. 2009;29(3):343-351.
37. Naamane H, El Maataoui O, Ailal F, et al. The 752delG26 mutation in the RFXANK gene associated with major histocompatibility complex class II deficiency: evidence for a founder effect in the Moroccan population. Eur J Pediatr. 2010;169(9):1069-1074.
38. Schmetterer KG, Seidel MG, Kormoczi U, et al. Two newly diagnosed HLA class II-deficient patients identified by rapid vector-based complementation analysis reveal discoordinate invariant chain expression levels. Int Arch Allergy Immunol. 2010;152(4):390-400.
39. Broides A, Shubinsky G, Parvari R, et al. MHC class 2 deficiency and X-linked agammaglobulinaemia in a consanguineous extended family. Int J Immunogenet. 2009;36(4):223-226.
40. Nekrep N, Geyer M, Jabrane-Ferrat N, Peterlin BM. Analysis of ankyrin repeats reveals how a single point mutation in RFXANK results in bare lymphocyte syndrome. Mol Cell Biol. 2001;21(16):5566-5576. (Pubitemid 32702460)
41. Genin E, Tullio-Pelet A, Begeot F, Lyonnet S, Abel L. Estimating the age of rare disease mutations: the example of Triple-A syndrome. J Med Genet. 2004;41(6):445-449. (Pubitemid 38788040)
42. Frazer KA, Ballinger DG, Cox DR, et al. A second generation human haplotype map of over 3.1 million SNPs. Nature. 2007;449(7164):851-861. (Pubitemid 47598626)
43. Sologuren I, Boisson-Dupuis S, Pestano J, et al. Partial recessive IFN-{gamma}R1 deficiency: genetic, immunological and clinical features of 14 patients from 11 kindreds. Hum Mol Genet. 2011;20(8):1509-1523.
44. Shearer WT, Rosenblatt HM, Gelman RS, et al. Lymphocyte subsets in healthy children from birth through 18 years of age: the Pediatric AIDS Clinical Trials Group P1009 study. J Allergy Clin Immunol. 2003;112(5):973-980. (Pubitemid 37412068)
45. Hervé M, Isnardi I, Ng YS, et al. CD40 ligand and MHC class II expression are essential for human peripheral B cell tolerance. J Exp Med. 2007;204(7):1583-1593. (Pubitemid 47048025)
46. Stephan V, Wahn V, Le Deist F, et al. Atypical Xlinked severe combined immunodeficiency due to possible spontaneous reversion of the genetic defect in T cells. N Engl J Med. 1996;335(21):1563-1567. (Pubitemid 26384751)
47. Hirschhorn R, Yang DR, Puck JM, Huie ML, Jiang CK, Kurlandsky LE. Spontaneous in vivo reversion to normal of an inherited mutation in a patient with adenosine deaminase deficiency. Nat Genet. 1996;13(3):290-295. (Pubitemid 26230494)
48. Wada T, Schurman SH, Otsu M, et al. Somatic mosaicism in Wiskott-Aldrich syndrome suggests in vivo reversion by a DNA slippage mechanism. Proc Natl Acad Sci U S A. 2001;98(15):8697-8702. (Pubitemid 32678090)
49. Antoine C, Muller S, Cant A, et al. Long-term survival and transplantation of haemopoietic stem cells for immunodeficiencies: report of the European experience 1968-99. Lancet. 2003;361(9357):553-560. (Pubitemid 36207472)
50. Bonduel M, Staciuk R, Figueroa C, et al. Unrelated cord blood transplantation and reducedintensity conditioning regimen for graft failure in a child with Major Histocompatibility Complex class II deficiency. Bone Marrow Transplant. 2009;43(10):817-818.